Upfront Briefing
Neurocrine is paying $2.9B for Soleno and its approved Prader-Willi syndrome medicine — a classic “buy revenue, not hope” move.
Amgen also put out positive Phase 3 topline for a subcutaneous Tepezza, nudging the franchise toward a more convenient (and defensible) form factor.
And on the private side, Stipple Bio launched out of stealth with an oversubscribed $100M Series A to push STP-100 and a precision oncology pipeline into early clinical work.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,582.7 |
+0.1% |
(4.0%) |
| Nasdaq 100 |
24,045.5 |
+0.1% |
(4.6%) |
| Russell 2000 |
2,530.0 |
+0.7% |
+0.9% |
| Healthcare (XLV) |
146.8 |
(0.6%) |
(5.2%) |
| Biotech (XBI) |
129.0 |
+0.3% |
+6.1% |
| Nasdaq Biotech (NBI) |
5,852.5 |
(0.4%) |
+2.6% |
| Clinical Trials (BBC) |
42.8 |
+1.0% |
+13.8% |
|
- Broader indices finished mixed, but small caps again led: the Russell 2000 gained +0.7% while the S&P 500 added just +0.1%, a sign investors were still willing to lean into higher-beta domestic exposure despite macro overhang from the Middle East and elevated oil.
- Biotech kept its relative bid: XBI rose +0.3% even as XLV fell (0.6%) and NBI slipped (0.4%), which fits a tape still rewarding SMID-cap catalyst and M&A exposure over diversified healthcare defensives.
- Market data: U.S. close Thu 02-Apr-2026.
The Big 3
|
1
|
Neurocrine to acquire Soleno Therapeutics for $2.9B
|
- Neurocrine Biosciences agreed to buy Soleno Therapeutics for $53 per share in cash, or roughly $2.9B, adding Vykat XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome.
- Why it matters: This is not a pipeline flyer: Neurocrine is buying a newly approved rare-disease asset that generated about $190M in its first nine months on the market in 2025, paying a 34% premium to secure a commercial product with real near-term revenue and multi-year expansion potential. For investors, that shifts the debate from binary development risk toward launch durability, peak-sales upside and whether Neurocrine can use Vykat XR to build a broader metabolic-disease franchise.
- Source: STAT
- More: Endpoints; BioSpace
|
|
2
|
Amgen posts positive Phase 3 topline for SC Tepezza
|
- Amgen reported positive Phase 3 topline results for subcutaneous Tepezza delivered via an on-body injector in adults with moderate-to-severe active thyroid eye disease, with the study meeting its primary and key secondary endpoints; 77% of patients achieved a proptosis response and the study showed a clinically meaningful reduction in proptosis of more than 3 mm.
- Why it matters: The key investment point is franchise defense, not just line-extension optics. Tepezza’s current IV regimen requires eight infusions spaced three weeks apart, so an on-body subcutaneous option could materially improve convenience, widen adoption and strengthen Amgen’s moat as TED competition tries to differentiate on route of administration. After Viridian’s recent TED readout, these data help keep the efficacy bar anchored to Tepezza while giving Amgen a cleaner lifecycle-management story.
-
Source:
Fierce Pharma
-
More:
PR
|
| 3 | Stipple Bio launches with $100M Series A |
-
Stipple Bio emerged from stealth with an oversubscribed $100M Series A to advance lead program STP-100 into early clinical studies and expand a precision oncology pipeline built on its Pointillist platform.
-
Why it matters:
The financing matters because it is large, syndicate-validated and thesis-setting: the round was co-led by RA Capital, a16z Bio+Health and Nextech Invest, with participation from Emerson Collective Investments, GV, LoLa Capital Partners and GordonMD. For investors, that signals real appetite for differentiated precision-oncology platforms despite a selective private market, and it puts Stipple in the bucket of well-capitalized next-wave oncology companies that could set valuation comps for platform peers.
-
Source:
Endpoints
-
More:
STAT; PR
|
Everything Else that broke
- White House seeks 12% cut to HHS in 2027 budget request. — BioPharma Dive
- Opus Genetics secures up to $155M in strategic financing from Oberland Capital to advance inherited retinal disease gene therapy programs. — BioSpace
- IDEAYA announces first-patient-in for Phase 1 study of IDE574, a dual KAT6/7 inhibitor in solid tumors. — PR
- BioNTech to shutter Singapore manufacturing site; job impacts reported. — BioSpace
- Replimune RP1 FDA decision eyed as signal of agency direction. — BioSpace
- FDA reversals in rare disease spotlight debate over external controls. — BioSpace
- Oncolytics to hold Type C FDA meeting on pelareorep pathway. — PR
- Anthropic acquires Coefficient Bio for $400M to expand into life sciences. — BioSpace
- Citeline: pharma pipeline stalls for first time in decades. — BioSpace
- BioCentury: Rocket gene therapy earns PRV among March FDA approvals. — BioCentury
- BioCentury: 1Q26 wrap tracks biotech stock tiers. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Neurocrine to acquire Soleno Therapeutics for $2.9B. — STAT
- Takeda ends Denali pact; Denali regains rights to DNL593. — BioSpace
- Akari partners with WuXi XDC on ADC payload targeting RNA splicing. — PR
VC / Private Financings
- Stipple Bio launches with an oversubscribed $100M Series A; co-led by RA Capital, a16z Bio+Health and Nextech Invest, joined by Emerson Collective Investments, GV, LoLa Capital Partners and GordonMD Global Investments. — PR
- Syneron Bio raises $150M Series B for its macrocyclic peptide platform; led by an unnamed international life-science fund, with Decheng Capital, CDH VGC, True Light Capital, Qiming Venture Partners, BioTrack, AstraZeneca and an ADIA subsidiary among participants. — Fierce Biotech
- Opus Genetics secures up to $155M in strategic financing from Oberland Capital, including $35M upfront and a $5M equity investment. — BioSpace
- BioCentury: Ambrosia’s $100M Series B was co-led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, with BVF Partners, Boulder Ventures, Janus Henderson and Samsara BioCapital also in the syndicate. — BioCentury
IPOs / Follow-Ons
- No notable biotech IPOs / follow-ons since the last edition.
Academic Corner - Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. — Nature Medicine
- Are India and China ready for a “chaotic surge” of generic obesity drugs?. — Lancet
- Clinical phenotyping improves choices of biologics in asthma. — Lancet
- Perioperative immunotherapy for resectable hepatocellular carcinoma. — Lancet
|
